Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2006-11-02 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Quarterly Report to Shareholders 8 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is a detailed quarterly report from Pharmaxis, covering product development, clinical trials, regulatory approvals, marketing activities, corporate news including board changes, intellectual property updates, and financial overview for the third quarter of 2006. It contains substantive financial data such as cash balances, sales figures, gross margin, interest income, and R&D expenses for the quarter. The presence of detailed financial and operational data for a period shorter than a full fiscal year, along with the focus on quarterly highlights and upcoming events, indicates this is an Interim / Quarterly Report. It is not merely an announcement or a presentation, but a comprehensive report with financial and operational details for the quarter. Q3 2006
2006-11-02 English
Commitments Test Entity - First Quarter Report 5 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly report' for entities admitted on the basis of commitments. It contains detailed financial data including consolidated cash flow statements for the quarter ended 30 September 2006, notes on payments to directors, financing facilities, reconciliation of cash, and compliance statements. The presence of actual financial statements and substantive financial data for a quarter indicates this is a comprehensive interim/quarterly financial report. The document length is 14,496 characters, which is substantial and not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2007
2006-10-30 English
Results of Meeting 5 pages ?Kb
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the outcomes of resolutions voted on at the Annual General Meeting (AGM) of Pharmaxis Ltd held on 26 October 2006. It includes voting results for various resolutions such as approval of the remuneration report, re-election of directors, remuneration of non-executive directors, grants of options to directors, and renewal of proportional takeover provisions. The content focuses on the official results of shareholder votes at the AGM, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not the AGM presentation materials themselves, nor is it an annual report or other financial report. It is also not a proxy solicitation or remuneration report but specifically the outcome of votes at the AGM. Therefore, the correct classification is DVA with high confidence.
2006-10-26 English
Appendix 3B 10 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is a new issue announcement related to securities, specifically unlisted employee options and additional securities issued by Pharmaxis Ltd. It includes detailed information about the class of securities, number issued, exercise prices, expiry dates, and terms of the options. The document references ASX (Australian Securities Exchange) requirements and is structured as a formal announcement of a securities issue and application for quotation of additional securities. There is no indication of financial statements, management discussion, or earnings data. The content is focused on capital changes and securities issuance rather than a full financial report or meeting materials. Therefore, this document fits the category of a Capital/Financing Update (CAP).
2006-10-26 English
Final Director's Interest Notice 2 pages ?Kb
Director's Dealing Classification · 95% confidence The document is titled 'Final Director's Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including holdings and associated interests, and the date the director ceased to be a director. There is no financial data, earnings information, or report content. The document is a report of personal share transactions or holdings by a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3441 characters, which is consistent with a notice rather than a full report. Therefore, the correct classification is DIRS with high confidence.
2006-10-26 English
Change of Director's Interest Notice x5 10 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y' and repeatedly refers to 'Change of Director's Interest Notice' with detailed information about changes in securities holdings by directors. It references ASX listing rules and the Corporations Act, indicating regulatory compliance filings related to insider trading or director share transactions. The content focuses on directors acquiring or disposing of securities, including options and shares, with dates and valuations. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure of director share dealings.
2006-10-26 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.